Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium.
Per Med
; 16(4): 325-333, 2019 07.
Article
in En
| MEDLINE
| ID: mdl-31313633
ABSTRACT
Implementing genome and exome sequencing in clinical practice presents challenges, including obtaining meaningful informed consent. Consent may be challenging due to test limitations such as uncertainties associated with test results and interpretation, complexity created by the potential for additional findings and high patient expectations. We drew on the experiences of research teams within the Clinical Sequencing Exploratory Research (CSER1) Consortium on informed consent for clinical genome and exome sequencing (CGES) to negotiate consensus considerations. We present six considerations for clinicians and 12 key points to communicate as they support patients in deciding whether to undergo CGES. These considerations and key points provide a helpful starting point for informed consent to CGES, grounded in the Clinical Sequencing Exploratory Research (CSER1) experience.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Exome Sequencing
/
Informed Consent
Type of study:
Guideline
/
Prognostic_studies
Aspects:
Ethics
Limits:
Humans
Language:
En
Journal:
Per Med
Year:
2019
Document type:
Article
Affiliation country:
United States